Close menu




December 29th, 2020 | 11:51 CET

BIGG Digital Assets, Lufthansa, Ballard Power - Breakthrough achieved!

  • Investments
Photo credits: pixabay.com

In March 2020, when the first lockdown was declared on the back of the Corona pandemic, bitcoin was at a low of USD 3,850. Now, at the end of the year, the most important cryptocurrency is rushing from one high to another. It is on the verge of breaking through the USD 30,000 mark. While price targets of over USD 80,000 are currently being called, more and more institutional investors enter the cryptocurrency market. A promising sign, also in general for companies in the blockchain universe.

time to read: 2 minutes | Author: Stefan Feulner
ISIN: CA0898041086 , DE0008232125 , CA0585861085

Table of contents:


    A player with many footholds

    The share of BIGG Digital Assets was able to benefit from the positive basic sentiment in recent weeks. The share price of the Canadian Company more than tripled from CAD 0.13 to currently CAD 0.47. The stock market value is now the equivalent of EUR 50.7 million. Although the hype around Bitcoin, Etherum & Co. provided tailwind, the Company's fundamental development was the decisive point for the strong performance. In this context, BIGG stands on two pillars.

    Sales of the internally developed crypto platform, Netcoins, have increased by more than 700% to over CAD 25 million since the beginning of the year. At Netcoins, the goal is to become the first certified trading platform in all of Canada. The registration application is underway. A positive sign should give the stock another significant boost.

    Security in cryptos

    The accusation that cryptocurrencies are not secure and are used for unclean transactions is to be combated by the Blockchain Intelligence Group division with its QLUE software. Here, suspicious monetary transactions are tracked and traced.

    It examines where the funds in question come from, where they go, and the profiles of the entities involved with greater forensic depth. Customers of the software include law enforcement agencies, banks and exchanges. Long-term contracts were signed this year with US Homeland Security and the US Department of Justice.

    Significantly oversubscribed

    In late November, Canadians closed a heavily oversubscribed private placement. The gross proceeds were USD 6.9 million. Here, much of the fresh money will be used to further development and research, expand the sales and marketing teams for BIGG international and Netcoins domestically, provide additional liquidity to handle trading in Netcoins, and increase the long-term Bitcoin investment portfolio.

    Currently, BIGG Digital Assets holds 189.5 bitcoin in its own portfolio. Although the young Company's share price has risen sharply, its broad positioning offers good opportunities in the long term.

    Lucrative follow-up order

    The partnership between Belgian bus manufacturer Van Hool and Ballard Power Systems continues to expand. The volume to date has included the supply of FC modules for more than 100 buses already in use in Germany, France, Denmark and Belgium. Now Ballard Power has received a follow-up order to supply additional fuel cell modules for ten H2 buses to be deployed in Emmen, the Netherlands, from 2022 as part of the JIVE 2 support program.

    Ballard plans to deliver the ten FC modules to Van Hool in 2021. The manufacturer will install them in hydrogen buses of the type A330, which will be used from 2022. In the meantime, Shell is building a hydrogen filling station and a 10 MW electrolysis plant on site for the on-site production of green hydrogen.

    Better than expected

    Lufthansa was able to exit trading yesterday with a significant gain of over 5% and crack the EUR 10 mark. The reason for this was the positive statements made by Lufthansa CEO Carsten Spohr. In this way, the cost side could be brought under control better than expected during the ongoing Corona pandemic.

    Of the EUR 9 billion in aid provided by the four home countries of Germany, Austria, Switzerland and Belgium, only EUR 3 billion has been drawn. "With around EUR 10 billion in available liquidity and sufficient balance sheet reserves, I can rule out over-indebtedness from today's perspective," Spohr said.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author



    Related comments:

    Commented by Juliane Zielonka on September 30th, 2022 | 10:59 CEST

    Biogen, XPhyto, BioNTech: Alzheimer's disease, depression, cancer - Pharma for life

    • Biotechnology
    • Pharma
    • Investments
    • Technology

    About 350 million people worldwide are affected by depression, a disorder of the brain. Each person also has a 16 to 20% chance of becoming depressed. Reason enough for the Canadian Company XPhyto Therapeutics to research a drug that is not addictive and can defeat the mental health-related medical condition. This week, Biogen, among others, achieved a breakthrough with an active substance against Alzheimer's disease. And if you follow the Bundesliga closely, you may be aware of the cases of testicular cancer among the players. Now BioNTech senses a new opportunity...

    Read

    Commented by Fabian Lorenz on September 29th, 2022 | 13:17 CEST

    Up to 200% share price potential: Kion, BioNTech, Aspermont in analyst check

    • Technology
    • Biotechnology
    • Investments

    The profit warning was a shock for Kion shareholders. Accordingly, the share price halved to EUR 20 in September alone. Now analysts are also slashing their estimates. The price targets for the forklift manufacturer are falling accordingly. Berenberg surprises with a high price target for the BioNTech share. At the same time, the analysts emphasize their hope for a continued generous dividend. Shareholders could thus be kept in good spirits until the next blockbuster. The roadshow of Aspermont in Germany has probably also created a good mood. At least the share price has jumped. The current consolidation could be an entry opportunity. Analysts see a price potential of over 200%.

    Read

    Commented by Carsten Mainitz on September 29th, 2022 | 12:01 CEST

    Verbio, Kleos Space, KWS Saat - This news is moving share prices!

    • Space
    • Technology
    • Investments

    Increased uncertainties in geopolitics, rampant inflation with exploding commodity and energy prices, and higher interest rates are making it increasingly difficult for companies to meet the forecasts they issued at the beginning of the year. Recent examples include battery manufacturer Varta and real estate financier Hypoport, which had to withdraw their annual targets. In addition, however, a number of companies have been able to surprise on the upside despite all the challenges.

    Read